<p>Sicart Associates LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的持股比例增加了 39.1%。该公司在本季度额外购买了 64,628 股后，持有该公司 230,083 股股票。Guardant Health 占 Sicart Associates LLC 投资组合的 3.9%，是其第五大持仓。截至最近向证券交易委员会的备案，Sicart Associates LLC 持有的 Guardant Health 股票约占 0.18%，价值 14,376,000 美元。</p>
<p>获取 <strong>Guardant Health</strong> 警报：</p>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>其他几家对冲基金最近也调整了对该股票的持有。Osaic Holdings Inc. 在第二季度将其在 Guardant Health 的持股比例提高了 118.6%。Osaic Holdings Inc. 目前持有 29,561 股该公司股票，价值 1,538,000 美元，此前在上个季度额外购买了 16,039 股。怀俄明州州政府在第二季度获得了 Guardant Health 的新头寸，价值约 567,000 美元。Castleark Management LLC 在第二季度购买了 Guardant Health 的新头寸，价值约 6,326,000 美元。Nikko Asset Management Americas Inc. 在第二季度将其在 Guardant Health 的持股比例提高了 49.6%。Nikko Asset Management Americas Inc. 目前持有 2,030,428 股该公司股票，价值 105,623,000 美元，此前在上个季度额外购买了 673,438 股。最后，加拿大人寿保险公司在第二季度将其在 Guardant Health 的持股比例提高了 8.1%。加拿大人寿保险公司目前持有 32,485 股该公司股票，价值 1,694,000 美元，此前在上个季度额外购买了 2,421 股。机构投资者和对冲基金持有该公司 92.60% 的股票。</p>
<h2>Guardant Health 股票下跌 2.6%</h2>
<p>GH 股票周三开盘价为 100.00 美元。Guardant Health, Inc. 的 52 周低点为 29.91 美元，52 周高点为 112.43 美元。该股票的市值为 126 亿美元，市盈率为 -31.15，贝塔值为 1.58。该公司的 50 日移动平均线为 90.23 美元，200 日移动平均线为 66.58 美元。</p>
<ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
<p>Guardant Health (NASDAQ:GH - 获取免费报告) 最近在 10 月 29 日发布了季度财报。该公司报告每股收益 (EPS) 为 -0.39 美元，超出分析师一致预期的 -0.48 美元，超出幅度为 0.09 美元。该公司本季度的收入同比增长 38.5%。去年同期，该公司每股收益为 -0.88 美元。整体来看，卖方分析师预计 Guardant Health, Inc. 本年度将发布 -2.9 的每股收益。</p>
<h2>分析师升级与降级</h2>
<p>GH 最近成为几份研究报告的主题。Guggenheim 将 Guardant Health 的目标价从 56.00 美元上调至 67.00 美元，并在 9 月 25 日的研究报告中给予该股票 &#34;买入&#34; 评级。摩根大通将 Guardant Health 的目标价从 90.00 美元上调至 120.00 美元，并在周一的研究报告中给予该股票 &#34;增持&#34; 评级。花旗集团将 Guardant Health 的目标价从 100.00 美元上调至 135.00 美元，并在 12 月 11 日的报告中给予该公司 &#34;买入&#34; 评级。瑞银集团将 Guardant Health 的目标价从 80.00 美元上调至 110.00 美元，并在 10 月 30 日的报告中给予该股票 &#34;买入&#34; 评级。最后，TD Cowen 将 Guardant Health 的目标价从 63.00 美元上调至 72.00 美元，并在 9 月 25 日的报告中给予该公司 &#34;买入&#34; 评级。23 位股票研究分析师对该股票给予了买入评级，1 位分析师对该公司给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，平均目标价为 94.57 美元。</p>
<ul>
<li>3 只快速增长的股票分析师预计价格翻倍</li>
</ul>
<p><strong>查看我们关于 Guardant Health 的最新研究报告</strong></p>
<h2>Guardant Health 内部交易</h2>
<p>在其他 Guardant Health 的新闻中，首席财务官 Michael Brian Bell 于 12 月 5 日星期五出售了 80,362 股该公司的股票。该股票以平均价格 103.14 美元出售，总交易额为 8,288,536.68 美元。交易后，首席财务官直接持有该公司 28,052 股股票，价值 2,893,283.28 美元。这代表其持股比例减少了 74.13%。该交易已在向证券交易委员会提交的文件中披露，相关文件可在 SEC 网站上获取。此外，首席技术官 Darya Chudova 于 12 月 8 日星期一出售了 13,664 股该公司的股票。该股票以平均价格 105.04 美元出售，总价值为 1,435,266.56 美元。交易后，首席技术官持有该公司 54,480 股股票，价值约 5,722,579.20 美元。这代表其持股比例减少了 20.05%。该交易的披露信息可在 SEC 文件中找到。内部人士在过去三个月内出售了价值 34,526,719 美元的 330,531 股公司股票。公司内部人士持有该公司 6.10% 的股票。</p>
<h2>Guardant Health 公司简介</h2>
<p>(免费报告)</p>
<p>Guardant Health, Inc.是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 响应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，这是一个集成的软件解决方案，旨在帮助临床和生物制药客户将接受检测的患者与具有潜在相关临床研究的可操作性变更连接起来；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，这是一个用于肿瘤演变和治疗耐药性的计算机模拟研究平台，适用于各种生物标志物驱动的癌症。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Guardant Health</li>
<li>什么是内幕交易？你可以从内幕交易中学到什么</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>3 只家居改善股票可以升级你的投资组合</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个聪明的买入机会</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Sicart Associates LLC 在第三季度将其在 Guardant Health, Inc. 的持股增加了 39.1%，目前拥有 230,083 股，价值 1438 万美元。分析师们提高了对 Guardant Health 的目标价格，Guggenheim、摩根大通、花旗集团、瑞士银行和 TD Cowen 均给予 “买入” 评级。该股票的平均评级为 “适度买入”，目标价格为 94.57 美元。首席财务官 Michael Bell 出售了 80,362 股，减少了 74.13% 的持股</p>

<p>Sicart Associates LLC grew its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 39.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 230,083 shares of the company's stock after purchasing an additional 64,628 shares during the quarter. Guardant Health makes up 3.9% of Sicart Associates LLC's holdings, making the stock its 5th biggest position. Sicart Associates LLC owned about 0.18% of Guardant Health worth $14,376,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Sicart Associates LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的持股比例增加了 39.1%。该公司在本季度额外购买了 64,628 股后，持有该公司 230,083 股股票。Guardant Health 占 Sicart Associates LLC 投资组合的 3.9%，是其第五大持仓。截至最近向证券交易委员会的备案，Sicart Associates LLC 持有的 Guardant Health 股票约占 0.18%，价值 14,376,000 美元。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 警报：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of the stock. Osaic Holdings Inc. lifted its stake in Guardant Health by 118.6% in the 2nd quarter. Osaic Holdings Inc. now owns 29,561 shares of the company's stock valued at $1,538,000 after buying an additional 16,039 shares in the last quarter. State of Wyoming acquired a new position in shares of Guardant Health during the second quarter valued at approximately $567,000. Castleark Management LLC purchased a new position in shares of Guardant Health in the second quarter valued at approximately $6,326,000. Nikko Asset Management Americas Inc. boosted its stake in shares of Guardant Health by 49.6% in the second quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company's stock worth $105,623,000 after acquiring an additional 673,438 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of Guardant Health by 8.1% during the second quarter. CANADA LIFE ASSURANCE Co now owns 32,485 shares of the company's stock worth $1,694,000 after purchasing an additional 2,421 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对该股票的持有。Osaic Holdings Inc. 在第二季度将其在 Guardant Health 的持股比例提高了 118.6%。Osaic Holdings Inc. 目前持有 29,561 股该公司股票，价值 1,538,000 美元，此前在上个季度额外购买了 16,039 股。怀俄明州州政府在第二季度获得了 Guardant Health 的新头寸，价值约 567,000 美元。Castleark Management LLC 在第二季度购买了 Guardant Health 的新头寸，价值约 6,326,000 美元。Nikko Asset Management Americas Inc. 在第二季度将其在 Guardant Health 的持股比例提高了 49.6%。Nikko Asset Management Americas Inc. 目前持有 2,030,428 股该公司股票，价值 105,623,000 美元，此前在上个季度额外购买了 673,438 股。最后，加拿大人寿保险公司在第二季度将其在 Guardant Health 的持股比例提高了 8.1%。加拿大人寿保险公司目前持有 32,485 股该公司股票，价值 1,694,000 美元，此前在上个季度额外购买了 2,421 股。机构投资者和对冲基金持有该公司 92.60% 的股票。</p>
</div><h2>Guardant Health Stock Down 2.6%</h2>
<div class="lb-trans"><h2>Guardant Health 股票下跌 2.6%</h2>
</div><p>GH stock opened at $100.00 on Wednesday. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43. The stock has a market cap of $12.60 billion, a price-to-earnings ratio of -31.15 and a beta of 1.58. The business has a fifty day moving average of $90.23 and a two-hundred day moving average of $66.58.</p>
<div class="lb-trans"><p>GH 股票周三开盘价为 100.00 美元。Guardant Health, Inc. 的 52 周低点为 29.91 美元，52 周高点为 112.43 美元。该股票的市值为 126 亿美元，市盈率为 -31.15，贝塔值为 1.58。该公司的 50 日移动平均线为 90.23 美元，200 日移动平均线为 66.58 美元。</p>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. The business's revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the company earned ($0.88) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.</p>
<div class="lb-trans"><p>Guardant Health (NASDAQ:GH - 获取免费报告) 最近在 10 月 29 日发布了季度财报。该公司报告每股收益 (EPS) 为 -0.39 美元，超出分析师一致预期的 -0.48 美元，超出幅度为 0.09 美元。该公司本季度的收入同比增长 38.5%。去年同期，该公司每股收益为 -0.88 美元。整体来看，卖方分析师预计 Guardant Health, Inc. 本年度将发布 -2.9 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><p>GH has been the topic of several recent research reports. Guggenheim lifted their target price on shares of Guardant Health from $56.00 to $67.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, September 25th. JPMorgan Chase &amp; Co. boosted their price target on shares of Guardant Health from $90.00 to $120.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday. Citigroup increased their price objective on shares of Guardant Health from $100.00 to $135.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. UBS Group boosted their target price on Guardant Health from $80.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 30th. Finally, TD Cowen increased their price target on Guardant Health from $63.00 to $72.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $94.57.</p>
<div class="lb-trans"><p>GH 最近成为几份研究报告的主题。Guggenheim 将 Guardant Health 的目标价从 56.00 美元上调至 67.00 美元，并在 9 月 25 日的研究报告中给予该股票 &#34;买入&#34; 评级。摩根大通将 Guardant Health 的目标价从 90.00 美元上调至 120.00 美元，并在周一的研究报告中给予该股票 &#34;增持&#34; 评级。花旗集团将 Guardant Health 的目标价从 100.00 美元上调至 135.00 美元，并在 12 月 11 日的报告中给予该公司 &#34;买入&#34; 评级。瑞银集团将 Guardant Health 的目标价从 80.00 美元上调至 110.00 美元，并在 10 月 30 日的报告中给予该股票 &#34;买入&#34; 评级。最后，TD Cowen 将 Guardant Health 的目标价从 63.00 美元上调至 72.00 美元，并在 9 月 25 日的报告中给予该公司 &#34;买入&#34; 评级。23 位股票研究分析师对该股票给予了买入评级，1 位分析师对该公司给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，平均目标价为 94.57 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师预计价格翻倍</li>
</ul>
</div><p><strong>View Our Latest Research Report on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Guardant Health 的最新研究报告</strong></p>
</div><h2>Insider Transactions at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 内部交易</h2>
</div><p>In other Guardant Health news, CFO Michael Brian Bell sold 80,362 shares of the company's stock in a transaction on Friday, December 5th. The stock was sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the transaction, the chief financial officer directly owned 28,052 shares in the company, valued at $2,893,283.28. This represents a 74.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CTO Darya Chudova sold 13,664 shares of the firm's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56. Following the transaction, the chief technology officer owned 54,480 shares of the company's stock, valued at approximately $5,722,579.20. This represents a 20.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 330,531 shares of company stock worth $34,526,719 in the last three months. Company insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Guardant Health 的新闻中，首席财务官 Michael Brian Bell 于 12 月 5 日星期五出售了 80,362 股该公司的股票。该股票以平均价格 103.14 美元出售，总交易额为 8,288,536.68 美元。交易后，首席财务官直接持有该公司 28,052 股股票，价值 2,893,283.28 美元。这代表其持股比例减少了 74.13%。该交易已在向证券交易委员会提交的文件中披露，相关文件可在 SEC 网站上获取。此外，首席技术官 Darya Chudova 于 12 月 8 日星期一出售了 13,664 股该公司的股票。该股票以平均价格 105.04 美元出售，总价值为 1,435,266.56 美元。交易后，首席技术官持有该公司 54,480 股股票，价值约 5,722,579.20 美元。这代表其持股比例减少了 20.05%。该交易的披露信息可在 SEC 文件中找到。内部人士在过去三个月内出售了价值 34,526,719 美元的 330,531 股公司股票。公司内部人士持有该公司 6.10% 的股票。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc.是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 响应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，这是一个集成的软件解决方案，旨在帮助临床和生物制药客户将接受检测的患者与具有潜在相关临床研究的可操作性变更连接起来；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，这是一个用于肿瘤演变和治疗耐药性的计算机模拟研究平台，适用于各种生物标志物驱动的癌症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>What is Insider Trading? What You Can Learn from Insider Trading</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Guardant Health</li>
<li>什么是内幕交易？你可以从内幕交易中学到什么</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>3 只家居改善股票可以升级你的投资组合</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个聪明的买入机会</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>RTX 因国防订单激增而飙升至历史新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Guardant Health, Inc. $GH 的持股量被 Sicart Associates LLC 增加